|
Rakesh K. Jain is the Andrew Werk Cook Professor of Tumor Biology at Massachusetts General Hospital in the Harvard Medical School. Dr. Jain primarily researches tumor pathophysiology. His work on cancer therapies led to discovery of an alternate use of Avastin, an anti-tumor cell pharmaceutical compound produced by Genentech, as an inhibitor for blood vessel growth necessary for tumor growth.〔( Study Said to Show Added Benefit of Genentech Breast Cancer Drug ). Andrew Pollack. New York Times. Retrieved January 17, 2007.〕 His award-winning work on tumor biology has been recognized by a number of professional recognitions, including the following awards in 2006: * Distinguished Service Award, Nature Biotechnology-Miami Symposium on Angiogenesis * Outstanding Achievement Award, Society of American Asian Scientists in Cancer Research * Robert L. Krigel Lecture, Fox Chase Cancer Center, Philadelphia * Alpha Chi Sigma Research Award, American Institute of Chemical Engineers * Benjamin Zweifach Distinguished Lecture, The City College, New York Dr. Jain received his B.Tech. degree from the Indian Institutes of Technology in Chemical Engineering in 1972 and received his M.Ch.E. and Ph.D. in Chemical Engineering from the University of Delaware in 1974 and 1976, respectively. He is a member of the National Academy of Engineering, the Institute of Medicine, and the National Academy of Sciences. ==Research work== Dr. Jain's Taming Vessels To Treat Cancer, published in Scientific American of January 2008, describes his work in solid cancer tumors. The main theory suggested in this article is to normalize the tumor blood vessels in order to improve the effect of chemotherapy and radiation treatment. This can be achieved using angiogenesis inhibitor drugs, and has shown promise in reducing edema in mice with glioblastoma. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Rakesh Jain」の詳細全文を読む スポンサード リンク
|